Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Brentuximab vedotin biosimilar?

Brentuximab Vedotin (Adcetris®) – a quick refresher

What it is Brentuximab vedotin is an antibody‑drug conjugate (ADC) that targets CD30, a protein expressed on the surface of certain lymphoma cells. The drug couples a monoclonal antibody (anti‑CD30) to a microtubule‑inhibiting cytotoxic agent (MMAE).
Approved uses (US & EU) Relapsed or refractory classical Hodgkin lymphoma (cHL), anaplastic large‑cell lymphoma (ALCL) (CD30+), and combination therapy with brentuximab + bendamustine/rituximab in cHL.
Typical dose 1.8 mg/kg IV every 3 weeks (max 180 mg) for 6 cycles; extended courses in relapsed settings are common.
Common side‑effects Peripheral sensory neuropathy (often dose‑limiting), neutropenia, fatigue, nausea, alopecia, and rare infusion reactions.

Biosimilar landscape for Brentuximab Vedotin

1. Why ADCs are hard to “clone”

An ADC is not just a protein; it’s a protein + a cytotoxic payload + a chemical linker. Small variations in any of those three components can change:

  • Target binding (affinity & kinetics)
  • Drug‑to‑antibody ratio (DAR)
  • Stability & release kinetics of the cytotoxic payload

Because of this, the regulatory pathway for an ADC biosimilar is more rigorous than for a conventional monoclonal antibody.

2. Current status (July 2024)

Company Candidate name Development stage Notes
Celltrion BvS (Celltrion‑BV) Phase III (US/Europe) First ADC biosimilar to enter late‑stage trials. Phase III data expected early 2025.
Samsung Biologics Brentuximab‑S Phase II Completed pivotal study in Asia; awaiting regulatory submission.
Bayer BV‑Biosimilar Phase II Early clinical data, no submission yet.
Bristol‑Myers Squibb Adcetris‑B N/A Internal project; no public data.

Bottom line: No biosimilar for Brentuximab vedotin has received full FDA or EMA approval yet. The most advanced candidates are in late‑phase trials, and we expect the first approvals, if the data look favorable, around 2025‑2026.

3. What the trials are looking for

Key endpoint Why it matters
Non‑inferiority in ORR and CRR vs. originator Demonstrates similar efficacy
Pharmacokinetics (Cmax, AUC, half‑life) Confirms similar exposure
Immunogenicity (anti‑drug antibodies) Avoids unexpected loss of efficacy or safety signals
Safety profile Must match or be better (especially neuropathy & neutropenia)

4. Potential advantages of an approved biosimilar

Feature Impact
Lower cost Biosimilars can be 20‑30 % cheaper than the reference, potentially expanding access.
Payer incentives Many insurers prefer the biosimilar in formulary placement.
Supply diversification Multiple manufacturers can reduce shortages.

How clinicians might use a future biosimilar

  1. Switching vs. de‑novo prescribing

    • Most guidelines (EMA, FDA) allow inter‑patient switching (changing a patient from Adcetris to the biosimilar) if the biosimilar is proven equivalent.
    • Intra‑patient switching (changing mid‑course) is less common but may be acceptable in certain jurisdictions after a single dose of the biosimilar.

  2. Monitoring

    • Neuropathy: Baseline and every cycle (using FACT‑GOG‑NTX or a similar scale).
    • Blood counts: CBC with differential before each infusion.
    • Infusion reactions: Standard pre‑medication (acetaminophen, antihistamine, steroids) as per local protocol.

  3. Documentation

    • Keep a clear record of the drug lot, manufacturer, and any adverse events.
    • Report serious adverse events to the pharmacovigilance program (FDA MedWatch or EMA EudraVigilance).

Quick reference: Brentuximab vedotin – Key facts

Item Detail
Mechanism Anti‑CD30 IgG1 + MMAE via a protease‑cleavable linker
Typical infusion time 30 min (first dose), 20 min thereafter
Contraindications Severe hypersensitivity to any component, uncontrolled neuropathy, severe neutropenia
Drug interactions Minimal; caution with agents that prolong QTc or cause neuropathy
Monitoring CBC, neuropathy assessment, liver enzymes (rare)
Cost (US) $5,000–$6,000 per infusion (approx.) – varies by payer

Bottom line

  • No FDA‑ or EMA‑approved biosimilar exists as of 2024.
  • Several candidates are in late‑phase trials (Celltrion’s BvS being the most advanced).
  • Once approved, the biosimilar is expected to offer cost savings and broaden access while maintaining the same efficacy/safety profile as Adcetris®.

What to do next?
Stay tuned to FDA and EMA announcements (they typically issue “biosimilar approval” news). If you’re treating a patient on Brentuximab, ask your pharmacy or institutional formulary team about the status of any pending biosimilar and whether they anticipate a switch in the near future.



Other Questions About Brentuximab :

What are the benefits of Brentuximab vedotin? Brentuximab patent expiry australia? Brentuximab vedotin? Brentuximab vedotin patent expiry? Brentuximab cost? Brentuximab price? Brentuximab vedotin which companies are developing a biosimilar?